Kind of related to this, I would think that other companies might be even more concerned that us. Imagine som mid to large pharma is working on a deal with cytodyn and they see cytodyn doing a deal for some other indication for the Chinese market. I would think they might want to jump in sooner to block this or they might rethink their partnership. This licensing process I’m sure is way more complicated than we know.